Bladder cancer patients’ stratification into risk groups relies on grade, stage and clinical factors. For non-muscle invasive bladder cancer, T1 tumours that invade the subepithelial tissue are high-risk lesions with a high probability to progress into an aggressive muscle-invasive disease. Detecting invasive cancerous areas is the main factor for dictating the treatment strategy for the patient. However, defining invasion is often subject to intra/interobserver variability among pathologists, thus leading to over or undertreatment. Computer-aided diagnosis systems can help pathologists reduce overheads and erratic reproducibility. We propose a multi-scale model that detects invasive cancerous areas patterns across the whole slide image. Th...
In pathology labs worldwide, we see an increasing number of tissue samples that need to be assessed ...
Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment stra...
Bladder cancer is the fourth most common cancer type in Norway, and tenth most common on a global sc...
Bladder cancer patients’ stratification into risk groups relies on grade, stage and clinical factors...
Bladder cancer patients' stratification into risk groups relies on grade, stage and clinical factors...
Up to 78% of patients with non-muscle invasive bladder cancer will develop a recurrence within 5-yea...
The most common type of bladder cancer is urothelial carcinoma, which is among the cancer types with...
Tumour budding has been described as an independent prognostic feature in several tumour types. We r...
Urothelial carcinoma is the most common type of bladder cancer and is among the cancer types with th...
Muscular-invasive bladder cancer (MIBC) is a common formof cancer which can necessitate complex trea...
The most common type of bladder cancer is urothelial carcinoma, which is among the cancer types with...
AIMS: The distinction between non-invasive (pTa) and invasive (pT1) non-muscle invasive bladder canc...
[EN] In recent times, bladder cancer has increased significantly in terms of incidence and mortality...
AIMS: The distinction between non-invasive (pTa) and invasive (pT1) non-muscle invasive bladder canc...
Abstract Bladder cancer is a prevalent malignancy with diverse subtypes, including invasive and non-...
In pathology labs worldwide, we see an increasing number of tissue samples that need to be assessed ...
Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment stra...
Bladder cancer is the fourth most common cancer type in Norway, and tenth most common on a global sc...
Bladder cancer patients’ stratification into risk groups relies on grade, stage and clinical factors...
Bladder cancer patients' stratification into risk groups relies on grade, stage and clinical factors...
Up to 78% of patients with non-muscle invasive bladder cancer will develop a recurrence within 5-yea...
The most common type of bladder cancer is urothelial carcinoma, which is among the cancer types with...
Tumour budding has been described as an independent prognostic feature in several tumour types. We r...
Urothelial carcinoma is the most common type of bladder cancer and is among the cancer types with th...
Muscular-invasive bladder cancer (MIBC) is a common formof cancer which can necessitate complex trea...
The most common type of bladder cancer is urothelial carcinoma, which is among the cancer types with...
AIMS: The distinction between non-invasive (pTa) and invasive (pT1) non-muscle invasive bladder canc...
[EN] In recent times, bladder cancer has increased significantly in terms of incidence and mortality...
AIMS: The distinction between non-invasive (pTa) and invasive (pT1) non-muscle invasive bladder canc...
Abstract Bladder cancer is a prevalent malignancy with diverse subtypes, including invasive and non-...
In pathology labs worldwide, we see an increasing number of tissue samples that need to be assessed ...
Bladder cancer is characterized by its frequent recurrence and progression. Effective treatment stra...
Bladder cancer is the fourth most common cancer type in Norway, and tenth most common on a global sc...